London
· Delayed Price · Currency is GBP · Price in GBXOncimmune Holdings Statistics
Total Valuation
Oncimmune Holdings has a market cap or net worth of GBP 17.16 million. The enterprise value is 21.51 million.
| Market Cap | 17.16M |
| Enterprise Value | 21.51M |
Important Dates
The next estimated earnings date is Friday, December 20, 2024.
| Earnings Date | Dec 20, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Oncimmune Holdings has 111.77 million shares outstanding. The number of shares has increased by 5,229.75% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 111.77M |
| Shares Change (YoY) | +5,229.75% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 11.47% |
| Owned by Institutions (%) | 29.56% |
| Float | 86.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 3.02 |
| EV / Sales | 17.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.98 |
Financial Position
The company has a current ratio of 1.14
| Current Ratio | 1.14 |
| Quick Ratio | 1.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.97 |
| Interest Coverage | -4.04 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 31,947 |
| Profits Per Employee | 187,237 |
| Employee Count | 38 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.81% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -32.81% |
| 50-Day Moving Average | 15.86 |
| 200-Day Moving Average | 17.64 |
| Relative Strength Index (RSI) | 49.06 |
| Average Volume (20 Days) | 369,803 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncimmune Holdings had revenue of GBP 1.21 million and earned 7.12 million in profits. Earnings per share was 0.00.
| Revenue | 1.21M |
| Gross Profit | 769,000 |
| Operating Income | -1.16M |
| Pretax Income | -2.93M |
| Net Income | 7.12M |
| EBITDA | -1.13M |
| EBIT | -1.16M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 911,000 in cash and 5.26 million in debt, giving a net cash position of -4.35 million or -0.04 per share.
| Cash & Cash Equivalents | 911,000 |
| Total Debt | 5.26M |
| Net Cash | -4.35M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -1.28M |
| Book Value Per Share | -0.00 |
| Working Capital | 385,000 |
Cash Flow
In the last 12 months, operating cash flow was -5.39 million and capital expenditures -10,000, giving a free cash flow of -5.40 million.
| Operating Cash Flow | -5.39M |
| Capital Expenditures | -10,000 |
| Free Cash Flow | -5.40M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 63.34%, with operating and profit margins of -95.14% and 586.08%.
| Gross Margin | 63.34% |
| Operating Margin | -95.14% |
| Pretax Margin | -241.27% |
| Profit Margin | 586.08% |
| EBITDA Margin | -93.08% |
| EBIT Margin | -95.14% |
| FCF Margin | -445.06% |
Dividends & Yields
Oncimmune Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5,229.75% |
| Shareholder Yield | -5,229.75% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Oncimmune Holdings has an Altman Z-Score of -9.5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.5 |
| Piotroski F-Score | n/a |